Cell cycle pathway alterations linked to worse survival and recurrence after liver transplant for HCC
New Liver Test Uses DNA to Predict Survival
A prospective single-center cohort study of 91 patients with hepatocellular carcinoma (HCC) after liver transplant found that cell cycle pat…
A new liver test analyzes tumor DNA to predict survival, revealing that even small cancers can be dangerous if they carry specific genetic c…
Postoperative pain score and NACRT predict anastomotic leakage in rectal cancer patients after anterior resection
One Pain Score Could Save Your Stoma
A retrospective cohort study of 901 rectal cancer patients who underwent anterior resection found an overall anastomotic leakage incidence o…
A simple pain rating after surgery is the best early warning sign for a dangerous leak in the bowel connection.
TQB2618 plus penpulimab shows 52% response in PD-1 refractory Hodgkin lymphoma
A New Drug Duo Revives Hope for Hodgkin Lymphoma After Immunotherapy Fails
A phase Ib single-arm trial in 21 Chinese patients with PD-1/PD-L1 inhibitor-refractory classic Hodgkin lymphoma found TQB2618 plus penpulim…
A new two-drug combination revived hope for Hodgkin lymphoma patients who failed prior immunotherapy, achieving a 52% response rate in early…
Phase 1 trial of zamtocabtagene autoleucel shows 75% response in relapsed/refractory B-cell NHL
Can a new cell therapy help lymphoma patients who have run out of options?
A Phase 1 clinical trial in 12 patients with relapsed or refractory B-cell non-Hodgkin lymphoma evaluated zamtocabtagene autoleucel at two d…
Five of 12 lymphoma patients treated with a new cell therapy achieved complete remission with no cancer return after five years and no sever…
Setidegrasib shows antitumor activity in advanced NSCLC and pancreatic cancer with p.G12D variants
A Drug That Shreds a Famous Cancer Target
This Phase 1 study evaluated setidegrasib in 203 patients with previously treated advanced solid tumors harboring p.G12D variants.
A first-of-its-kind drug called setidegrasib shrank lung and pancreatic tumors in patients with a cancer mutation that has frustrated drugma…
225Ac-DOTA-IBA shows pain relief and imaging responses in bone metastases preliminary study
Small preliminary study shows promising pain relief with new bone cancer treatments
A preliminary study of 14 patients with bone metastases found that 225Ac-DOTA-IBA at 3.7 MBq per cycle led to pain relief in 92.9% after the…
New bone cancer drugs relieved pain in 93% of patients and improved daily function with no severe side effects in this early study.
Chemoradiotherapy reduces cardiorespiratory fitness and increases fatigue in patients with HPV-positive oropharyngeal cancer
Chemotherapy and radiation may reduce fitness in patients with HPV-related throat cancer
This small observational study assessed changes in physiological parameters in 20 patients with HPV-positive oropharyngeal cancer undergoing…
Chemotherapy and radiation for HPV throat cancer drop fitness, muscle, and strength within weeks, with fatigue worsening by nearly 50 points…
FDA Approves Onureg (azacitidine) for Continued Treatment of Adult AML Patients in First Remission After Intensive Chemotherapy
The FDA approved a new oral drug called Onureg for certain leukemia patients in remission
FDA approved Onureg for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission or complete …
FDA approved oral drug Onureg for leukemia patients in remission who cannot complete intensive curative therapy.
FDA Approves Ondansetron Injection, USP (ondansetron hydrochloride) for prevention of nausea and vomiting associated with emetogenic cancer chemotherapy and postoperative nausea/vomiting
FDA approves a new injection to help prevent nausea and vomiting from cancer treatment and surgery
FDA approved ondansetron injection for prevention of nausea and vomiting associated with emetogenic cancer chemotherapy and postoperative na…
FDA approves new injection to prevent nausea and vomiting from cancer treatment and surgery for children as young as one month old.
Penpulimab plus chemotherapy significantly improved progression-free survival in recurrent or metastatic nasopharyngeal carcinoma
New drug plus chemo delays cancer growth in advanced nasopharyngeal cases
This randomized, double-blind phase 3 trial evaluated penpulimab combined with cisplatin/carboplatin and gemcitabine versus placebo plus che…
Adding penpulimab to chemotherapy delays cancer growth by nearly three months in advanced nasopharyngeal cases, offering new hope for patien…
Anti-PD-1 plus chemoradiotherapy improved event-free survival in MS1 subtype nasopharyngeal carcinoma patients compared with chemoradiotherapy alone
New Test Picks Who Wins From Cancer Drug
This review analyzed pooled data from two Phase III randomized clinical trials involving 407 patients with locoregionally advanced nasophary…
A new test identifies which nasopharyngeal cancer patients will survive longer when adding immunotherapy to standard radiation and chemother…
Becotatug vedotin shows antitumor activity in pretreated recurrent or metastatic nasopharyngeal carcinoma
A New Drug Shows Promise for Tough-to-Treat Nasopharyngeal Cancer
A phase IIa single-arm trial of 61 patients with platinum-refractory recurrent or metastatic nasopharyngeal carcinoma found an objective res…
For patients with a hard-to-treat head and neck cancer who have few treatments left, a new experimental therapy is showing encouraging resul…